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Abstract
Currently, one of the biggest controversies in the field of cardiac regenerative
medicine revolves around the ability of cardiomyocytes to proliferate. In contrast to
the long-held hypothesis that the heart is a terminally differentiated, post-mitotic
organ, some studies have suggested that the heart is capable of undergoing lim-
ited regeneration following injury. Others have reported induction of cardiomyocyte
proliferation following various treatments, mostly in vitro. Conventional tools such
as BrdU labeling fail to distinguish between mitotic events and other phenomena
such as endoreduplication or poly-nucleation, thus making it difficult to assess car-
diomyocyte proliferation. The present study presents a novel and innovative way to
unambiguously study cardiomyocyte proliferation by use of a cell division probe to
identify cells that undergo mitosis. The system utilizes a mutant form of the mitotic
regulator cytoskeleton-associated protein 2 (CKAP2). CKAP2 remains cytoplasmic
during interphase, but translocates to the nucleus following mitotic cell division. Usu-
ally, wild-type CKAP2 is degraded via the ubiquitin-proteosome pathway following
translocation to the nucleus; however, by mutation of a destruction motif, the protein
persists in the daughter nuclei following cell division. Thus, this non-degradable mu-
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tant of CKAP2 (ndCKAP2) can be used to track mitotic events - ndCKAP2 should
remain cytoplasmic in quiescent cells but appear nuclear in cells that have undergone
mitosis. Here, the efficacy of ndCKAP2 as a cell division probe is demonstrated; in
particular, ndCKAP2 is demonstrated to be easily visualizable, unambiguously track
mitotic events, and present a relatively long half-life (and is therefore integrative in
output). It is expected that future studies will utilize this molecular probe system
to investigate cardiomyocyte proliferation in vivo under a variety of physiological
and pathological conditions, and allow for assessment of various proposed clinical
therapies.
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Chapter 1
Introduction
1.1 Clinical Context
Heart failure is a major public health problem, both in the United States and
around the world; indeed, an estimated 5.1 million Americans have heart failure, and
one in nine death certificates attribute heart failure as a cause of death [1]. Car-
diomyocyte deficiency, often the result of cardiovascular disease, underlies one of the
leading causes of heart failure. For example, myocardial infarction (MI) can result in
loss of 25% of ventricular cardiomyocytes within several hours after onset of disease
[2, 3]. Diseases of cardiac overload, such as hypertension, also activate numerous
pathways for apoptosis, necrosis, and autophagy of cardiac tissue, leading to slow
death of cardiomyocytes over a number of years [2, 4]. Loss of cardiomyocytes is
not solely the outcome of cardiac pathologies; studies have shown that aging alone is
associated with a loss of ∼1 g of myocardium per year [5]. In the context of an aging
population, there is thus a need to investigate and assess the mechanisms underlying
1
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cardiac damage and repair.
Loss of cardiomyocytes results in hypertrophy of existing myocytes, often accom-
panied by polyploidization of cells, to try to maintain force generation and contraction
[2, 5]. The response to severe damage is more complex, and involves significant tis-
sue/matrix remodeling and cytokine recruitment of inflammatory cells [6, 7]. Fibrosis
and formation of scar tissue also occurs at the injury site. These mechanisms, how-
ever, have been shown to be insufficient for recovery of cardiac function [8]. The
failure of the heart to adequately respond to injury has thus led to a long-standing
belief that the heart is incapable of regeneration [7].
1.2 Can the Heart Regenerate?
In contrast to the traditional viewpoint of the heart as a post-mitotic or termi-
nally differentiated organ, a great deal of recent evidence has suggested that the adult
mammalian heart possesses some, albeit limited, renewal capacity [9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22]. A highly novel study by Bergmann et al. [9] mea-
sured carbon-14 levels incorporated into genomic DNA of patient myocardial cells
after aboveground nuclear bomb tests during the Cold War. Bomb tests resulted in
a worldwide pulse of 14C, which was incorporated into plants through photosynthesis
and subsequently into humans that ate labeled plants. Following the Limited Nuclear
Test Ban Treaty in 1963, 14C levels dropped rapidly; this provided the researchers
with pulse-chase experiment conditions in which a cardiomyocyte could be dated by
determining when DNA 14C levels matched atmospheric levels. The authors demon-
strated that many patient cardiomyocytes were younger than the patient themselves;
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various computational modeling strategies demonstrated that ∼45% of patient car-
diomyocytes would be renewed over the course of a lifetime. The rate of turnover was
calculated as approximately 1% per year at age 20; however, the rate drops to 0.4%
at age 75.
Another study by Mollova et al. [10] presented similar results. In this study,
cardiomyocytes were dissociated from hearts of patients aged 0 - 59 who had passed
away of non-cardiovascular-related conditions. The samples were then analyzed by
immunohistochemistry staining for phospho-histone H3 (PHH3, a mitotic marker)
and mitotic kinesin-like protein (MKLP-1, a centralspindlin component required for
completion of cytokinesis). The authors determined that myocyte turnover is 100%
per year at age 0, but drops to 1.9% at age 20 and 0.04% for subjects older than
40. Moreover, cardiomyocyte number in the left ventricle increases 3.4 fold in the
first 20 years of life. These results correspond well to calculations determined by
Bergmann et al. [9]. Furthermore, the results validate that cardiomyocyte renewal
occurs throughout life; however, the rate of renewal decreases with aging and may be
a contributive factor in poor heart regeneration in the elderly [5].
There has, however, been controversy in terms of calculating rates of cardiomy-
ocyte renewal in patients without cardiovascular disease. In particular, Kajstura et
al. have reported significantly higher rates of cardiac renewal in healthy adult mam-
malian hearts [11, 12, 13]. In one study, similar to that conducted by Mollova et al.,
the authors analyzed immunohistochemistry for Ki67, PHH3, and aurora B kinase
(three frequently used mitotic markers) in cardiomyocytes derived from hearts of pa-
tients aged 19 to 104 years. They calculated that annual rate of myocyte turnover in
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females was approximately 10% at age 20 and slightly lower in men; moreover, they
demonstrated turnover rates of approximately 32 - 40% for patients aged 100 [11].
According to these results, all of the myocytes of the heart are replaced between 11
and 15 times from 20 to 100 years of age. In another study, Kajstura et al. per-
formed 14C dating to calculate that the myocyte component of the heart is replaced
entirely approximately 8 times over the course of an individual’s life [12]. These re-
sults stand in stark contrast to the more modest rates of cardiac renewal predicted
by Bergmann et al. and Mollova et al. and have invited scrutiny. Indeed, the rates
calculated by Kajstura et al. are on par with proliferation rates of cell types such as
cardiac fibroblasts and endothelial cells [12, 14]. Some have argued that a substantial
portion of the predict myocyte turnover may be attributable to phenomena such as
polyploidization (a possibility that will be considered later) or multinucleation [14].
Nevertheless, these studies taken as a whole all point to the capacity of the healthy
adult heart to undergo cardiomyocyte renewal throughout life. The results of these
various studies are summarized in Figure 1.1.
Cardiac renewal is not limited to the healthy heart; indeed, studies have shown
some, if minimal, regenerative response in cardiomyopathy as well [12, 15, 16]. In
hearts of patients who had died within 4 - 12 days of myocardial infarction, mitotic
figures and newly formed cardiomyocytes were identified adjacent to the infarct, with
lower rates of renewal identified at regions further from the infarct zone [15]. In par-
ticular, these cardiomyocytes identified at the peri-infarct region have been shown to
be small and generally mononucleated, suggesting cardiomyogenesis [16].
Thus, there is significant evidence to suggest that the view of the heart as a static,
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Figure 1.1: Summary of recent literature values for annual cardiomyocyte turnover.
A variety of methods have been utilized in the literature, including 14C labeling
and immunohistochemistry analysis of tissue sections, to demonstrate cardiomyocyte
renewal in vivo. While there are still discrepancies between various reported values
of cardiomyocyte renewal, there is general acceptance that the heart possesses some,
albeit limited, renewal capacity. Figure adapted from [14] under a Creative Commons
3.0 CC-BY license.
non-regenerative organ is outdated; renewal occurs both under normal physiological
and disease conditions. Practical evidence from clinical experiences show that these
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innate strategies of cardiac turnover are insufficient to prevent or fully ameliorate
cardiomyocyte loss due to aging and cardiovascular disease. However, understanding
the mechanisms underlying cardiomyocyte renewal may uncover avenues for potential
future therapeutics for loss of cardiomyocytes and development of heart failure.
1.3 Do Cardiomyocytes Proliferate?
Two hypotheses have been put forward to explain how cardiomyocyte renewal oc-
curs in vivo: proliferation of existing cardiomyocytes and differentiation of stem cells
into cardiomyocytes [14, 17, 23]. The latter mechanism has been pursued with great
enthusiasm, motivated in large part by the discovery of a variety of progenitor-like
populations resident to or mobilizing to the myocardium [24, 25, 26]. Here, however,
the role of cardiomyocyte proliferation is considered.
There is precedence in non-mammalian species for considering cardiomyocyte pro-
liferation as a mechanism for cardiac renewal and repair. For example, newts and
other urodele amphibians have been shown to undergo cardiac regeneration via car-
diomyocyte proliferation [27, 28]. These organisms can survive and recover from
excision of up to 50% of ventricle. Oberpriller et al. identified mitotic figures oc-
curring adjacent to the damaged area, suggesting dedifferentation/proliferation of
existing cardiomyocytes [27]. Another classic model of cardiomyocyte proliferation is
the zebrafish [29, 30]. Zebrafish can fully recover from excision of 20% of ventricular
mass within two months, replacing the wound with newly generated cardiomyocytes
rather than scar tissue [29]. In an elegant fate-mapping study, Kikuchi et al. identi-
fied proliferation of existing cardiomyocytes as being responsible for cardiac recovery
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[30]. In this experiment, the researchers generated a transgenic zebrafish in which a
tamoxifen-inducible Cre-mediated recombination event would induce consitutive ex-
pression of green fluorescent protein (GFP) reporter in pre-existing cardiomyocytes.
Thus, following excision of the ventricle, a progenitor cell-mediated recovery would
result in the generation of GFP− cardiomyocytes, while renewal from existing car-
diomyocyte proliferation would produce GFP+ cardiomyocytes. It was found that fol-
lowing ventricular resection, the majority of regenerated ventricular apex was GFP+,
supporting a cardiomyocyte proliferation-hypothesis for cardiac regeneration in ze-
brafish. Interestingly, it was found that zebrafish with mutations in proliferation
pathways underwent fibrosis and scar formation similar to that found in adult mam-
mals following cardiac injury [29]. These results suggest that fibrosis of cardiac tissue
is a response to inhibition of or lack of vigor in cardiomyocyte proliferation.
Zebrafish heart structure differs somewhat from mammalian heart. For example,
mammalian hearts are four-chambered with double-circulation, while fish hearts are
two-chambered with single circulation. Fish hearts also generally pump blood with
lower force, which may affect cardiomyocyte physiology. Moreover, the majority of
zebrafish cardiomyocytes remain mononucleated throughout life, while mammalian
cardiomyocytes become binucleate (and often multinucleate) shortly after birth [31].
However, a number of studies have shown that neonatal mammal hearts retain pro-
liferative capacity throughout development and shortly after birth [22, 31, 32]. Car-
diomyocyte proliferation plays a key role in heart development during embryogenesis
[31]. Moreover, in mice younger than 7 days of age, excision of up to 15% of ventricular
myocardium is met with full recovery within two months and minimal scarring [22].
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Fate mapping studies similar to those conducted in zebrafish identify proliferation of
existing cardiomyocytes as being responsible for cardiac regeneration. Investigators
identified cardiomyocytes near the injured area with myofibrillar breakdown charac-
teristic of cardiomyocyte dedifferentiation and proliferation [22, 32]. After 7 days of
age in mice, however, cardiac injury does not result in cardiomyocyte regeneration;
instead, fibrosis and scar formation occurred [22]. This loss of regenerative potential
coincides with the binucleation of mammalian cardiomyocytes in early development.
Thus, mammalian cardiomyocytes have proliferative capacity throughout embryogen-
esis and until shortly after birth, but this capacity may be inhibited or downregulated
in a large portion of myocytes in the first week after birth.
The extent to which adult mammalian cardiomyocytes retain proliferation capac-
ity has been highly controversial. A number of studies have documented the pres-
ence of mitotic figures (via immunhistochemistry analysis of mitotic markers such as
phospho-histone H3, Ki67, and others) in both normal and diseased cardiac tissue
[12, 13, 15, 16, 19, 20]. In particular, Beltrami et al. have shown that the number of
myocytes positive for Ki67 increase significantly in hearts isolated from patients who
died shortly after myocardial infarction; these mitotic figures were largely clustered
around the infarct area [15]. Contrastingly, Hesse et al. reported that following infarc-
tion, cardiomyocytes bordering the infarct region do not undergo mitosis [33]. Here,
the authors utilized annilin, a component of the contractile ring with characteristic
subcellular localization during mitosis, as a marker of cell division. The researchers
analyzed cardiomyocytes in eGFP-annilin transgenic mice and found no evidence of
proliferation following injury. Several groups have sought to address the discrepancies
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between these findings [14, 17, 32]. Indeed, analysis of cardiomyocyte proliferation is
complicated by a number of experimental challenges, including unambiguously identi-
fying cardiomyocytes from other cell types, differentiating between mitosis and other
phenomena (such as polyploidization/endoreduplication), and identifying what may
be rare mitotic events. These issues are considered in more detail later. The poten-
tial role that stem and progenitor cells may play in adult mammalian cardiac renewal
and regeneration must also be considered. Hsieh et al. performed an elaborate fate-
mapping analysis to demonstrate the role of stem cells in replenishing cardiomyocytes
following infarction. In this study, the researchers used doubly-transgenic mice to gen-
erate tamoxifen-inducible expression of GFP reporter protein in 82.7% of pre-existing
cardiomyocytes [21]. During normal aging of up to one year, the proportion of GFP+
cardiomyocytes did not change, suggesting that any renewal under healthy conditions
occurred without input from non-cardiomyocyte cell types. However, following injury,
the percentage of GFP+ cardiomyocytes dropped to 67.5% near the infarct zone, sug-
gesting replacement of cardiomyocytes from some progenitor source. In a similar
fate-mapping study, Malliaras et al. identify cardiomyocyte proliferation as being the
primary mechanism of cardiac renewal under healthy conditions in adult mammalian
heart, but show that progenitor cell recruitment is the predominant mechanism of
recovery following injury [16]. In this model, normal renewal is mediated by a small,
constantly cycling population of uninucleate cardiomyocytes. These cells, however,
are insufficient to regenerate the heart during conditions of injury, resulting in re-
cruitment of progenitors to the infarct area. Though these results suggest a key role
of stem cell recruitment in ameliorating cardiac injury, they do not conclusively rule
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out the possibility of cardiomyocyte proliferation during injury response. Taken as a
whole, these results support the possibility that cardiomyocyte proliferation occurs
in the adult mammalian heart, albeit at rates too small to sufficiently regenerate the
heart following age- or disease-mediated cardiomyocyte loss.
1.4 Factors Regulating Cardiomyocyte
Proliferation
The fact that adult mammalian cardiomyocytes may maintain proliferative capac-
ity has led to an interest in investigating mechanisms regulating proliferation. Thus
far, a number of genes, miRNAs, proteins, and transcription factors have been shown
to be involved in controlling and/or inducing cardiomyocyte proliferation, including
SV40 large T antigen [18, 31, 34]; c-myc [18]; homeobox gene MeisI [35]; miR-195,
miR-590-3p, miR-199a-3p, and miR-133a [31, 36]; Hippo signalling pathway [31]; cy-
clins and cyclin-dependant kinases [18, 31]; FOXO1 and FOXO3 transcription factors
[37]; and others. Moreover, the modes of regulation have shown to be both negative
and positive [31]. The tremendous variety of pathways and machinery involved in the
regulation of cardiomyocyte proliferation suggest that it is a highly controlled phe-
nomenon that is activated and inhibited by a number of temporal cues throughout
development and maturation.
The possibility that cardiomyocytes may proliferate has generated investigation
into induction of proliferation as a therapeutic approach. To this end, a number of
cocktails of growth factors have been developed to promote cardiomyocyte prolifer-
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ation [17, 18, 31, 38, 39, 40, 41, 42]. Engel et al. proposed the inhibition of p38
mitogen-activated protein kinase (p38 MAPK) as an avenue for inducing cardiomy-
ocyte proliferation [17, 40, 41]. Through a combination of p38 MAPK inhibitor (p38
MAPKi) and fibroblast growth factor 1 (FGF1) treatment, the researchers were able
to induce gene expression corresponding to dedifferentiation and cell-cycle re-entry
in cardiomyocytes in culture [40]. Moreover, FGF1/p38 MAPKi therapy resulted in
increase in phosphorylated histone-3 staining and cell number in culture, with car-
diomyocytes demonstrating sarcomeric dedifferentiation characteristic of proliferative
cardiomyocytes. In another study, Bersell et al. identified the tyrosine kinase receptor
ErbB4 as playing a role in myocardial regeneration in vivo; in particular, inactivation
of ErbB4 results in reduced cardiomyocyte regeneration following infarct, while high
ErbB4 expression corresponds to improved cardiac regeneration [38, 39]. The authors
utilized the growth factor neuregulin1 (NRG1), an agonist of the ErbB4 receptor, to
promote cardiomyocyte cell division in vitro [39]. Interestingly, the authors found
that NRG1 induced proliferation in mononucleate myocytes, but not in binucleate
or multinucleate myocytes. This may suggest that, developmentally, multinucleation
acts an inhibitor of cardiomyocyte proliferation [31]. In a third study, Kühn et al.
utilized periostin, an activator of cardiomyocyte membrane integrins, to induce prolif-
eration [42]. All three therapies, when utilized in vivo following myocardial infarction,
improved cardiac function and regeneration and reduced fibrosis [39, 41, 42]. How-
ever, it is not fully clear whether cardiomyocyte proliferation is the main source of
improved cardiac function. While all three approaches show convincing induction
of cell-cycle gene expression and increase in staining for various mitotic markers in
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culture, each therapy also promotes angiogenesis in vivo, which may suggest reasons
for cardiac improvement following infarction other than just proliferation of existing
cardiomyocytes. These therapeutics provide hope that targeting pathways involved
in regulation of cardiomyocyte proliferation may serve as alternative therapeutic av-
enues to cell therapy [17]. However, the in vivo results demonstrate the need for an
assay to unambiguously demonstrate myocyte proliferation in animal models.
1.5 Challenges in Assessing Cardiomyocyte
Proliferation
Identifying cardiomyocyte mitosis in vivo is an endeavour filled with a number of
major experimental challenges [14, 17, 32]. First and foremost, the architecture of car-
diac tissue makes it challenging to correctly identify cardiomyocytes in tissue sections,
even when stained with cardiomyocyte-specific cytoplasmic markers. Several authors
have shown that cardiomyocytes display irregular shape in vivo, with a number of fi-
broblasts and inflammatory cells found in spaces between cardiomyocytes [32, 43]. In
a particularly critical study, Ang et al. compared conventional confocal microscopic
analysis of cardiomyocyte tissue sections (with and without a membrane marker) to a
gold standard of a transgenic mouse in which nuclear-localized -galactosidase report
was expressed only in cardiomyocytes, with >99% of cardiomyocytes labeled thus
[43]. The authors found that conventional methods could misidentify cardiomyocytes
up to 10% of the time. A number of techniques have been utilized to try and improve
fidelity of cardiomyocyte identification, including labeling cardiomyocyte nuclei with
Chapter 1: Introduction 13
markers such as Nkx2.5 or various transgenic mice models [21, 32, 44]. Others have
aimed to use labour-intensive dispersion techniques to specifically isolate cardiomy-
ocytes from tissue samples prior to analysis [9, 19]. These methods have improved
accuracy of identification of cardiomyocytes; however, considerations of tissue archi-
tecture and the presence of proliferative non-myocyte cells must be taken into account
when determining proliferation of cardiomyocytes.
Two particularly popular tools for assessing proliferation are bromodeoxyuridine
(BrdU) and Ki67, shown in Figure 1.2. BrdU is synthetic analogue of thymidine in
which a methyl group of thymidine is replaced by a bromine group. During S phase
of the cell cycle, cells replicate DNA. When pulsed with BrdU during this period,
cells may incorporate BrdU into DNA instead of thymidine; subsequently, immuno-
histochemistry can be utilized to identify cells that have undergone DNA synthesis
(see Figure 1.2a). Ki67 is nuclear protein thought to be associated with cell prolif-
eration and ribosomal RNA transcription. Ki67 is known to be expressed through
all active stages of cell cycle (though not during quiescent states such as G0); how-
ever, while during interphase expression is within the cell nucleus, Ki67 expression
relocates to the chromosomal surface upon initiation of M-phase (see Figure 1.2b).
The predictability and general ease of use associated with BrdU and Ki67 have made
them popular markers for proliferation in various cancers [45]. Likewise, both have
been used in a number of studies to assess cardiomyocyte proliferation. However,
unlike most cancers, cardiomyocytes are known to undergo abortive variants of cell-
cycle such as endocycle (in which DNA synthesis occurs without subsequent mitosis)
and endoreduplication (in which mitosis is initiated but cytokinesis does not occur)
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(a) BrdU (b) Ki67
Figure 1.2: (a) BrdU labeling (green) of primary E12 mouse cortex cells. BrdU is a
thymidine analogue, and is thus incorporated into the DNA of cells undergoing DNA
synthesis when provided in the culture media. Taken from [46]. (b) Ki67 labeling
of HeLa cells. In interphase cells (left), Ki67 shows a diffuse nuclear localization;
however, upon onset of mitosis (right), Ki67 localization changes to the surface of
chromosomes. Taken from [47] under license from Springer Science. While both
BrdU and Ki67 have been popular proliferation markers, they fail to unambiguously
distinguish between mitosis and abortive cell cycle.
[18, 32]. The net result of these phenomena may be increased DNA content and ploidy
in the cell or increased numbers of nuclei per cell without actual cell division. Neither
BrdU nor Ki67 distinguish between these various cell cycle variants and actual com-
pletion of mitosis, making them poor markers to assess cardiomyocyte proliferation.
Some researchers have aimed to compensate for the issue of ambiguity by utilizing
markers that closely correspond to progress through and termination of mitosis. For
example, phospho-histone H3 (PHH3) has been frequently used as a marker of mitosis
in vitro[48]. Phosphorylation of histone H3 (which occurs site-specifically at serine
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10 on the histone protein) occurs almost exclusively during mitosis. Moreover, the
intensity and localization of phosphorylation can often be used to track progression of
the cell throughout each phase of mitosis (see Figure 1.3a). Thus, antibody staining
of cells allows for an accurate assessment of proliferation [48]. Mitotic kinesin-like
protein (MKLP-1) has also been used as a marker for mitosis. MKLP-1 is a compo-
nent of the centralspindlin complex, a key part of the contractile ring of cytokinesis
[49]. Thus, immunostaining for MKLP-1 allows identification of cells about to un-
dergo cytokinesis and complete mitosis (see Figure 1.3b). A third approach utilizes
anillin to track progression through mitosis. Anillin is a scaffolding protein that, like
MKLP-1, plays a role in mediating cytokinesis [33]. The localization of anillin within
the cell can be used to track cell cycle; in particular, anillin localizes to the contrac-
tile ring in early cytokinesis and to the midbody in late cytokinesis (see Figure 1.3c).
In this sense, anillin can also unambiguously mark cells undergoing mitosis. These
three markers are shown in Figure 1.3. However, cardiomyocytes in vivo undergo
mitosis very rarely [14, 32]. For example, using MKLP-1, Mollova et al. report that
in cardiomyocyte samples derived from patients aged 0 - 1, 0.016 ± 0.003% of car-
diomyocytes were found to be in cytokinesis; this number drops to 0.005 ± 0.005%
for subjects in the second decade of life [10]. The authors identified no myocytes in
cytokinesis past age 20. These extremely small numbers, coupled with relatively high
standard deviations, indicate the extreme rarity of mitotic cardiomyocytes found in
vivo. Markers such as as PHH3, MKLP-1, and anillin, while allowing for unambigu-
ous identification of mitosis, provide only snapshots in time. Given that mitosis itself
comprises only a relatively small portion of cell cycle, markers must be devised to al-
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(a) PHH3
(b) MKLP-1
(c) Anillin
Figure 1.3: Examples of PHH3, MKLP-1, and anillin labeling. (a) PHH3 labeling
(red) of HeLa cells in various stages of mitosis. Taken from [50] under license from the
American Association of Cancer Research. (b) MKLP-1 labeling (green). MKLP-1
forms a key part of the contractile ring during cytokinesis. Taken from [10].(c) Anillin
labeling (green). In interphase, anillin localizes to the nucleus; however, as mitosis
occurs, it localizes first to the contractile ring and then to the midbody. Taken
from [33] under a Creative Commons 2.5 BY-NC license. While these three markers
unambiguously mark mitotic events, their short half-life following mitosis makes them
inefficient for tracking what may be extremely rare mitotic events in cardiomyocytes.
low for sensitive analysis of cardiomyocyte proliferation in vivo.
These challenges highlight the need for a new method of detecting cardiomyocyte
proliferation. In particular, such a tool must be easily visualized and/or quantified,
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unambiguous, and integrative in nature. Here, a potential molecular probe that
satisfies these criteria is described.
1.6 ndCKAP2 as a Probe for Proliferation
Cytoskeleton-associated protein 2 (CKAP2) may serve as a potential probe for
assessing cardiomyocyte proliferation in vivo. CKAP2 has been shown to play a
number of key roles in regulating mitosis [51, 52, 53, 54]. In particular, CKAP2 has
been shown to have microtubule-stabilizing properties and is responsible for main-
tenance of mitotic spindle bipolarity [51]. Moreover, CKAP2 is a known substrate
for the anaphase-promoting complex/Cdh1, suggesting a key role for the protein in
mitotic spindle dynamics [52]. Overexpression and/or mutation of CKAP2 can result
in a number of microtubule abnormalities and spindle defects in mitosis [52]. CKAP2
has been shown to be upregulated in a number of malignant cancers, while knock-
down in vitro has resulted in reduction of rate of cell growth [53].
Similar to mitotic markers such as PHH3, MKLP-1, and anillin, the localization
of CKAP2 corresponds well to progression through cell cycle (Figure 1.4). During
interphase, CKAP2 is primarily associated with microtubules. In the early stages
of mitosis, CKAP2 is similarly associated with spindle microtubules. However, at
cytokinesis, CKAP2 translocates to the midbody microtubules and the nuclei of the
newly forming daughter cells [51, 52]. Shortly after mitosis, this translocated CKAP2
is broken down by the anaphase-promoting complex in a ubiquitin ligase-mediated
proteolysis pathway [52]. The unambiguous change in localization of CKAP2 through-
out mitosis, and particularly during cytokinesis, has led to some investigators utilized
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Figure 1.4: Localization of CKAP2 throughout cell cycle. In prophase, CKAP2 is
found with a cytoplasmic localization, and is strongly associated with microtubules.
After completion of mitosis, however, CKAP2 becomes nuclear in localization. Taken
from [52].
CKAP2 as a mitotic probe for studying proliferation in samples from breast cancer
patients [54]. However, like some of the above markers, CKAP2 only identifies cells
as they are undergoing mitosis rather than cells that have already undergone mitosis ;
it is not integrative in nature.
In studying the interaction between CKAP2 and the anaphase-promoting com-
plex, Hong et al. identified a destruction motif in CKAP2 that is recognized by Cdh1
for CKAP2 breakdown following completion of mitosis [52]. This motif, named the
KEN box after the three residues comprising the structure, is conserved across higher
eukaryotes and involved in the ubiquitin ligase-mediated degradation of CKAP2. By
mutation of the three residues to alanine, Hong et al. generated a mutant which re-
sisted breakdown following mitosis (Figure 1.5). This mutant, named non-degradable
CKAP2 (ndCKAP2), presents a cytoplasmic localization during interphase. Upon
completion of mitosis, however, the protein translocates to nucleus in an easily vi-
sualized and unambiguous manner. Moreover, because the nuclear ndCKAP2 is not
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Figure 1.5: Comparison of CKAP2 (WT) and ndCKAP2 (KEN mutant). While
CKAP2 is degraded within thirty minutes after completion of mitosis via ubiquitin-
mediated pathways, nuclear ndCKAP2 is not broken down. Taken from [52].
broken down after completion of mitosis, it makes it possible to identify not just cells
that are undergoing mitosis at the time of analysis, but cells that have undergone mi-
tosis. In this sense, ndCKAP2 serves as an integrator for mitotic events occuring in
tissue. Given these characteristics, ndCKAP2 may be an appropriate tool for mitotic
experiments, including the investigation of cardiomyocyte proliferation in vivo. The
present study aims to establish ndCKAP2 as a valid and useful molecular probe for
assessing proliferation in a visualizable, unambiguous, and integrative manner.
1.7 Hypothesis and Aims
It is hypothesized that ndCKAP2 can serve as an easily visualized, unambiguous,
and integrative molecular probe for assessing proliferation. This hypothesis will be
tested in three aims:
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• Generation of a fluorescent cell division probe. A genetic construct for
an eGFP-ndCKAP2 fusion protein will be engineered, and a lentiviral-based
expression system carrying this construct will be generated. These constructs
will be tested by either transfection or viral transduction of both HeLa and
HEK293 (two common transformed cell lines) cells and neonatal rat ventricular
cardiomyocytes (NRCMs, a primary cell line).
• Validation of ndCKAP2 as an unambiguous marker of proliferation.
Cell-cycle studies in proliferative cells will be used to quantifiably assess whether
ndCKAP2 remains cytoplasmic in quiescent cells and translocates to the nucleus
solely following completion of mitosis.
• Determination of the half-life of nuclear ndCKAP2. It is presumed that
at some point nuclear ndCKAP2 is broken down or exported from the nucleus,
if very slowly. Given that a novel aspect of the ndCKAP2 probe is its ability
to persist in the nucleus following completion of mitosis, it is necessary to know
how long this persistence will last. Calculation of the half-life of ndCKAP2
once translocated into the nucleus (and comparison with other commonly used
probes) will be used as a metric to assess the integrative nature of ndCKAP2.
The goal of the current study is to demonstrate the use of ndCKAP2 as a powerful
tool for measuring proliferation. It is believed that the characteristics of ndCKAP2
will make it an ideal probe for addressing the controversy of cardiomyocyte prolifer-
ation under physiological and post-injury conditions, and will be the focus of future
investigations.
Chapter 2
Materials and Methods
2.1 Genetic Constructs and Lentiviral Production
Generation of an enhanced green fluorescent protein (eGFP) fusion ndCKAP2
construct (pEGFP-C2 ndCKAP2) has been previously described [52]. The eGFP-
ndCKAP2 coding sequence was PCR amplified with Pfu DNA polymerase (Agilent)
using the following primers: Forward - 5’ CACCATGGTGAGCAAGGGCGAG 3’;
Reverse - 5’ TTATGTTGTATCAGCCTCATAGTACACCCG 3’. The amplification
cycle was: 95◦C (30 sec) → 60◦C (15 sec) → 72◦C (3 min), repeated for 25 cy-
cles. This produced DNA with a CACC sequence at the 5’ end. The purified PCR-
amplified product was then subcloned into pLenti6/V5 vector harboring human cy-
tomegalovirus (CMV) promoter and rous sarcoma virus (RSV) enhancer using the
Directional TOPO R© cloning kit (Invitrogen) as per the manufacturer instructions.
In this system, an overhang in the cloning vector (GTGG) charged with topoiso-
merase recognizes and invades the 5’ end of the PCR product; thus, subcloning can
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be performed with high efficiency without addition of a ligase. Identity of construct
was assessed by investigating products of BamHI/XhoI and SmaI restriction enzyme
digests on an agarose gel. Sequencing was also performed at DNA Core (University of
Louisville School of Medicine) to verify fidelity of construct. To generate additional
construct for introduction into cells, pLenti6-eGFP-ndCKAP2 was used to transform
competent Stbl3 E. coli. DNA was subsequently harvested via Miniprep or Midiprep
kits (Qiagen). All other constructs used in experimentation, such as GFP-C2 control,
were obtained from Dr. Kyung Hong at the UofL Department of Molecular Cardiol-
ogy.
To generate lentivirus for expression of eGFP-ndCKAP2 in primary mammalian
cell lines, the ViraPowerTM Lentiviral Expression System was used according to man-
ufacturers instructions. 293FT cells were transfected using Lipofectamine 2000 (Invit-
rogen) with pLenti6-eGFP-ndCKAP2 along with an optimal viral packaging mix con-
taining pLP1, pLP2, and pLP/VSVG plasmids (provided by manufacturer). Virus-
containing supernatant was harvested 72 hours later and titered prior to use.
2.2 Cell Culture, Transfection, and Transduction
HeLa, HEK293, and NIH3T3 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum (FBS) and penicillin/streptomycin.
Neonatal rat ventricular cardiomyocytes (NRCMs), isolated from 1 - 2 day old Sprague-
Dawley rats, were graciously provided by Dr. Steven Jones at the UofL Department
of Molecular Cardiology. NRCMs were cultured in DMEM containing 5% FBS, peni-
cillin/streptomycin, and Vitamin B12. In addition, during the first 2 - 3 days of
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culture, NRCMs were incubated with 0.1 mmol/L BrdU to prevent outgrowth of any
contaminating fibroblasts. Human cardiac stem cells (CSCs) were graciously provided
by Matthew Keith at the University of Louisville Department of Molecular Cardiology,
and were isolated based on c-Kit expression from endocardial biopsies from consenting
patients with ischemic cardiomyopathy. CSCs were cultured in F12 media containing
10% FBS, 2.5 units erythropoietin, 10 ng/mL basic fibroblast growth factor (bFGF),
and 0.2 mM glutathione. Cells were maintained in a humidified culture incubator at
37◦C with 5.0% CO2. Proliferative cells (HeLa, HEK293, NIH3T3, and CSCs) were
subcultured every 2 - 3 days.
Transfection of cells was performed using Lipofectamine 2000 following the manu-
facurer’s instructions. Liposome-DNA complexes were removed five hours after trans-
fection. Lentiviral transduction was performed by mixing virus (titered in DMEM)
with polybrene (Sigma) and adding to cells. During viral transduction, cells were
cultured in DMEM containing 10% FBS without antibiotics. 24 hours after trans-
duction, cells were washed and media was changed to DMEM containing 10% FBS
and penicillin/streptomycin.
2.3 Cell Cycle Synchrony
To synchronize cells in S-phase, a single thymidine block was performed. Cells
were transfected five hours prior to initiation of the block. Cells were then incubated
with 2 mM thymidine (Sigma, dissolved in PBS) for 20 hours. Subsequently, the cells
were washed thrice with warmed PBS and released into fresh media to be assayed.
In some experiments, a tighter synchrony was desired, and thus a double thymidine
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block was performed instead. To perform double thymidine block, cells were incu-
bated with 2 mM thymidine for 19 hours. Subsequently, the cells were washed thrice
with warmed PBS and released into fresh media for 9 hours. During the last five
hours of this release, cells were transfected. The cells were then blocked a second
time with 2 mM thymidine. Cells were then washed thrice with warmed PBS and
released into fresh media to be assayed.
To synchronize cells in G2/M boundary, a thymidine-nocodazole block was per-
formed. Cells were transfected five hours prior to initiation of the thymidine block.
Cells were then incubated with 2 mM thymidine for 20 hours. Subsequently, the
cells were washed thrice with warmed PBS and released into media containing 1 µM
nocodazole (Sigma, dissolved in DMSO). After 12 hours, warmed media was used to
detach rounded mitotic cells from the culture plate by gentle pipetting. Cells were
then re-plated in fresh media to be assayed.
2.4 Immunofluorescence Staining and Imaging
Cells grown on glass cover-slips were fixed in 3.7% formaldehyde solution in PBS
for 10 minutes at room temperature, and subsequently permeabilized in 0.5% Triton-
X-100 in PBS for 10 minutes. Following incubation in a blocking solution of 5% bovine
serum albumin in PBS for 30 minutes, cells were incubated with primary antibody
(diluted in blocking solution) for 1 hour at room temperature. Cells were then washed
thrice with PBS and incubated with the secondary antibody (diluted in blocking so-
lution) for 1 hour at room temperature. Cells were then washed thrice with PBS
and counterstained with DAPI. Coverslips were mounted on glass slides with Fluo-
Chapter 2: Materials and Methods 25
romount (TM) aqeuous mounting medium (Sigma). Primary antibodies were diluted
as follows: GFP (Abm), 1:300; PHH3 (Millipore), 1:2000; and α-tubulin, 1:1000. All
Alexa-fluor conjugated secondary antibodies were acquired from Invitrogen and used
at a dilution of 1:1000.
Images were collected using either an EVOS fluorescent cell imaging system (Life
Technologies) or an Axiovision fluorescent microscope (Carl Zeiss). Images were an-
alyzed using ImageJ software and manipulated and overlaid using the open-source
Gnu Image Manipulation Program (GIMP). For calculations based on fluorescence,
the following formula was used to correct signal for background and determine a value
of fluorescence per unit area (FPUA) in a given region:
FPUA =
Integrated Density− Cell Area×Mean Fluorescence of Background
Cell Area
2.5 Flow Cytometry and FACS Analysis
Cells were fixed in cold 70% ethanol overnight or longer. Prior to analysis, cells
were washed with PBS containing 1% bovine serum albumin and subsequently stained
in a propidium iodide (PI) solution containing 50 g/mL PI, 0.1% sodium citrate, 0.3%
NP-40, 100 µg/mL RNase A, 1% bovine serum albumin, and PBS for 20 minutes at
room temperature. PI is a DNA dye, and thus serves visualize progression through cell
cycle. Profiles of PI-stained cells were obtained using a FASCalibur system (Becton
Dickinson) and analyzed using FlowJo software (Tree Star). Cells were sequentially
gated based on SSC-A vs FSC-A, FSC-W vs FSC-H, and SSC-W vs SSC-H to dis-
criminate against doublets or debris, as well as on GFP expression.
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Results
3.1 Generation of pLenti6-eGFP-ndCKAP2
eGFP-ndCKAP2 was PCR amplified from a previously generated construct [52]
and subcloned into pLenti6/V5 vector using the Directional TOPO R© cloning kit (In-
vitrogen). This strategy obviated the need for a ligase to mediate the subcloning
process. The vector map of pLenti6-eGFP-ndCKAP2 (referred to from here as GFP-
ndCKAP2) is shown in Figure 3.1.
To validate the identity of the construct, GFP-ndCKAP2 was subject to restriction
enzyme digest; the products of the digest were subsequently analyzed through agarose
gel electrophoresis. In the first reaction (outlined in Figure 3.2a), GFP-ndCKAP2
was subject to digest from the restriction enzymes BamHI and XhoI. The sites of
cleavage for BamHI and XhoI are found on the pLenti6 vector flanking the insert;
an additional XhoI cut site is found between the GFP and ndCKAP2 open reading
frames. Thus, when run on a gel, this reaction should produce three fragments - a
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Figure 3.1: Vector map of pLenti6-GFP-ndCKAP2. The plasmid was engineered by
subcloning the GFP-ndCKAP2 open-reading frame into the lentiviral vector through
the use of the TOPO R©cloning kit (Invitrogen).
7.0 kilobase (kb) fragment corresponding to the pLenti6 vector, a 2.0 kb fragment
corresponding to the ndCKAP2 sequence, and a 0.7 kb fragment corresponding to
the eGFP sequence. Thus, the BamHI/XhoI digest served to validate the insertion
of both the fluorescent protein GFP and the proliferation marker ndCKAP2 into the
pLenti6 vector.
The purpose of the second digest (outlined in Figure 3.2b), performed utilizing
the restriction enzyme SmaI, was to validate the orientation of the GFP-ndCKAP2
insert into pLenti6 vector. The target cleavage sequence for SmaI is found within
the ndCKAP2 open reading frame as well as within the vector. In the case that the
insert was in the correct orientation, restriction enzyme digest would produce an 8.1
kb fragment and a 1.6 kb fragment. However, if the insert orientation were reversed,
the digest would produce a 7.8 kb fragment and a 1.9 kb fragment.
Chapter 3: Results 28
GFP ndCKAP2Bam
HI
XhoI
XhoI
0.7 kB 2.0 kB
Vector Size = 7.0 kB
7.0 kb
2.0 kb 0.7 kb
(a) BamHI/XhoI restriction enzyme digest
GFP ndCKAP2
Sma1
Sm
a1
1.6 kB
8.1 kb
1.6 kb
Sma1
Sm
a1
1.9 kB
7.8 kb
1.9 kb
GFPndCKAP2
(b) Sma1 restriction enzyme digest
Figure 3.2: Schematics of Restriction Enzyme Experiments. In (a), the construct
is subject to BamHI/XhoI digest; this allows for verification that the GFP and nd-
CKAP2 open reading frames were inserted into the vector. In (b), the construct is
subject to SmaI digest to verify if the insert is in the correct orientation (top) or
reversed (bottom).
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Figure 3.3 shows the results of the restriction enzyme digests. The column labeled
1 and 2 served as control cases, and represent digest with BamHI and XhoI alone,
respectively. Column 3 shows the results of BamHI/XhoI digest; as can be seen,
the expected fragment sizes are observed, validating the inclusion of both GFP and
ndCKAP2 into the pLenti6 vector. Column 4 shows the results of SmaI digest. As
can be seen, the resultant fragment sizes match the predicted values shown in Figure
3.2b, verifying that the GFP-ndCKAP2 fusion protein was inserted into the pLenti6
vector in the correct orientation.
While restriction enzyme digests allow for general validation of subcloning, several
other aspects of the GFP-ndCKAP2 fusion protein had to be assessed prior to ap-
10kb
  8kb
  6kb
  5kb
  4kb
  3kb
2.5kb
   2kb
1.5kb
   1kb
0.5kb
BamHI XhoI
BamHI/
  XhoI SmaI
1 2 3 4
Figure 3.3: Analysis by restriction enzyme digest of pLenti6-GFP-ndCKAP2.
Columns 1 - 4 represent digest with BamHI alone, XhoI alone, BamHI/XhoI, and
SmaI respectively. Comparison with Figure 3.2 validates the successful generation of
the lentiviral vector.
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                    . . . GAT CCA CTA GTC CAG TGT GGT GGA ATT GAT CCC TT| C ACC   ATG GTG AGC AAG GGC . . .
pLenti6-GFP-ndCKAP2 . . . GAT CCA CTA GTC CAG TGT GGT GGA ATT GAT CCC TT  C ACC   ATG GTG AGC AAG GGC . . .
pLenti6 Vector Sequence
2402                    
Overhang
                   in Insert                    
eGFP Open Reading Frame
1 
Figure 3.4: Sequencing of pLenti6-GFP-ndCKAP2 at the 5’ end of the GFP-
ndCKAP2 insert. The top row represents expected sequences of the pLenti6 vec-
tor and wild-type eGFP open reading frame. The numbers represent the base pair
position along the sequence. In the engineering pLenti6-GFP-ndCKAP2, a CACC
overhang generated in the insert is invaded by a corresponding sequence in the pLenti6
vector. As can be seen, the sequences of the engineered vector match with the ex-
pected sequences; moreover, the eGFP protein remains in frame. Further sequencing
demonstrated the absence of point mutations in the engineered construct (not shown
here).
plication. First, it was necessary to ensure that the GFP-ndCKAP2 coding sequence
had been inserted in the correct reading frame (or whether a frameshift mutation had
occurred during the subcloning process). Secondly, the construct needed to be evalu-
ated to ensure that no point mutations had occurred. To validate these two aspects,
GFP-ndCKAP2 was sequenced. Figure 3.4 shows a comparison of the pLenti6 vector
as well as the eGFP open reading frame to the GFP-ndCKAP2 insert at the site of
insertion into the vector. As can be seen, the GFP-ndCKAP2 insert is maintained in
frame. Sequencing also demonstrated the absence of point mutations from the final
GFP-ndCKAP2 vector (results not shown here).
These results validate the subcloning of the GFP-ndCKAP2 fusion protein con-
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struct into the lentiviral vector. This vector was subsequently transfected into 293FT
cells, along with a mix of genes for viral packaging proteins, to generate lentivirus
carrying the GFP-ndCKAP2 expression construct.
3.2 GFP-ndCKAP2 can be expressed in tranformed
and primary cell lines
To determine whether the engineered GFP-ndCKAP2 successfully produced ex-
pression of the fusion protein in cells, HeLa cells were transfected with the GFP-
ndCKAP2 construct and subsequently analyzed via immunohistochemistry. CKAP2
is known to have microtubule-stabilizing properties during mitosis, and remains closely
associated with the microtubules and cytoskeletal structure of the cell through inter-
phase and the early stages of mitosis [51, 52]. To verify this association, HeLa cells
transfected were stained with α-tubulin, a structural subunit of microtubules, after
transfection. As can be seen in Figure 3.5, cytoplasmic GFP-ndCKAP2 localization
corresponds well to α-tubulin expression in the cell. Subsequently, the protein translo-
cates to the nucleus, as is verified by staining for DAPI, a DNA dye. Representative
examples of both nuclear and cytoplasmic ndCKAP2 are seen in Figure 3.5.
To test expression of the GFP-ndCKAP2 fusion protein, three commonly used
immortalized cell lines (HeLa, HEK293, and NIH3T3) were transfected with the GFP-
ndCKAP2 construct (Figure 3.6). Similarly, HEK293 cells as well as two primary cell
lines (CSCs and NRCMs) were transduced with the lentivirus carrying the GFP-
ndCKAP2 expression construct (Figure 3.7). All cell types tested readily express the
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Figure 3.5: Subcellular localization of GFP-ndCKAP2. In the cytoplasmic localiza-
tion (top), ndCKAP2 shows strong association with microtubules, as visualized by
α-tubulin staining. The nuclear localization (bottom) is verified by co-staining with
DAPI (a nuclear dye).
fusion protein GFP-ndCKAP2; moreover, this expression can be readily visualized
under fluorescent microscopy. Initially, all cells express GFP-ndCKAP2 with a cy-
toplasmic localization. However, within one day of expression, all proliferative cell
types (HeLa, HEK293, NIH3T3, and CSCs) demonstrated cells with nuclear local-
ization of GFP-ndCKAP2. Examples of cytoplasmic and nuclear localization of the
fusion protein are shown in higher magnification the insets of Figures 3.6 and 3.7. In
contrast, cells with nuclear GFP-ndCKAP2 were not seen in NRCMs, as would be
expected of a cell type that does not proliferate in vitro.
Chapter 3: Results 33
(a) HeLa cells tranfected with GFP-ndCKAP2.
(b) HEK293 cells transfected with GFP-ndCKAP2.
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(c) NIH3T3 cells transfected with GFP-ndCKAP2
Figure 3.6: HeLa, HEK293, and NIH3T3 cells transfected with GFP-ndCKAP2. In
all cells, expression is clear and readily visible within 24 hours of transfection. All
cell types demonstrated cells with nuclear localization of ndCKAP2 within one day of
onset of expression. Insets show examples of cells with both cytoplasmic and nuclear
localization of GFP-ndCKAP2.
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(a) HEK293 cells transduced with GFP-ndCKAP2-carrying lentivirus.
(b) CSCs transduced with GFP-ndCKAP2-carrying lentivirus.
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(c) NRCMs transduced with GFP-ndCKAP2-carrying lentivirus.
Figure 3.7: HEK293 cells, CSCs, and NRCMs transduced with GFP-ndCKAP2-
carrying lentivirus. Expression is clear and readily visible within 48 - 72 hours post-
transduction. Nuclear localization of ndCKAP2 was seen in HEK293 cells and CSCs
after expression of GFP-ndCKAP2, as seen in the insets. However, quiescent NRCMs
do not demonstrate nuclear ndCKAP2 even after a week in culture, supporting the
claim that ndCKAP2 only translocates to the nucleus following completion of mitosis.
These experiments validate the expression of GFP-ndCKAP2 in both immortal-
ized and primary cell lines (by both liposome-mediated transfection and lentiviral
transduction). Moreover, the cytoplasmic localization was verified in all cell types
and shown to be microtubule-associated, and the presence of nuclear-localized GFP-
ndCKAP2 was noted in all proliferative cell types.
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3.3 Appearance of nuclear ndCKAP2 corresponds
with completion of mitosis in synchronized cells
To quantitatively validate that nuclear GFP-ndCKAP2 serves as an unambiguous
marker of proliferation, the appearance of nuclear ndCKAP2 was tracked in HeLa cells
synchronized by double thymidine block. Figure 3.8a shows a schematic of the double
thymidine experiment. After double thymidine block, cells were synchronized at the
G1/S border (Figure 3.8b). After release, the cells synchronously proceeded through
cell cycle, entering into G2 phase at approximately 6 hours, and completing mitosis
between 8 - 12 hours. Progression of HeLa cells transfected with GFP-ndCKAP2
through cell cycle after double thymidine block is visualized by flow cytometry anal-
ysis of PI staining, shown in Figure 3.8c. The percentage of cells in G1, S, and G2/M
phases respectively was quantified using computational analysis based on built-in cell
cycle progression models in FlowJo, and plotted in Figure 3.8d. As can be seen by
the increase in percentage of the number of cells in G1 phase at 14 hours, approxi-
mately 31.3% of cells re-entered and progressed through cell cycle following release
from double thymidine block. To further demonstrate progression through cell cycle,
cells were harvested at 4, 6, 8, 10, and 12 hours post-release and stained with PHH3;
representative images are shown in Figure 3.8e.
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(a) Schematic of double thymidine experiment.
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(b) PI staining profile for asynchronous cell population (left) and population synchronized
at G1/S by double thymidine block (right).
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(c) PI staining profile for synchronous cell populations released from double thymidine
block.
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(d) Cell cycle analysis for synchronous cell populations released from double thymidine
block. Time in hours.
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(e) PHH3 (red) staining at serial-time points following release from double thymidine block.
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Figure 3.8: Progression of HeLa cells through cell cycle following synchronization
through double thymidine block. (a) Schematic of the double thymidine block ex-
periment. After completion of both sequential blocks, >99% of cells are arrested in
G1/S; release from the block causes cells to progress synchronously through cell cycle.
(b - d) Validating progression through cell cycle via PI analysis. About 30% of cells
proceed synchronously through cell cycle. (e) PHH3 staining at serial time-points fol-
lowing release from double thymidine block. Mitotic figures begin to appear 8 hours
post-release, as supported by the PI data.
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Figure 3.9 shows the analysis of localization of GFP-ndCKAP2 in HeLa cells re-
leased from double thymidine block. Cells were assayed at 4, 6, 8, 10, 12, and 14 hours
post-release, stained for GFP and DAPI, and visualized under fluorescent microscope.
Quantification was done by assessing the number of cells expressing cytoplasmic and
nuclear localization of GFP-ndCKAP2 in several random fields of view on the slide.
>150 cells were counted per slide, and four slides were assayed per time point. As
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Figure 3.9: Appearance of Nuclear ndCKAP2 in HeLa cells synchronized by double
thymidine block. As can be seen, very few nuclear ndCKAP2 figures appear prior to
8 hours post-release from double thymidine block. This corresponds well to the cell
cycle release profiles shown in Figure 3.8. Data shown is mean ± SD, with N = 4
and > 150 cells counted per sample.
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can be seen, increase in the proportion of cells showing nuclear localization of GFP-
ndCKAP2 correlates strongly with progression through cell cycle. Very few (∼ 0%
of observed cells at 4 hours and <2% at 6 hours) show nuclear localization of GFP-
ndCKAP2 up until 6 hours; however, a marked increase occurs between 6 and 10
hours post-release from double thymidine block. This increase also corresponds with
the increase in cells staining positive for PHH3, as shown in Figure 3.8e, suggesting
a connection between change in localization and completion of mitosis. At 14 hours,
the percentage of cells showing nuclear localization of GFP-ndCKAP2 is 30.11% ±
1.53%, which matches the percentage of cells that progressed synchronously through
cell cycle as determined by computational modeling. Figure 3.10 shows representative
images of cells at various assayed time points. Visual inspection verifies the increase
in cells showing nuclear GFP-ndCKAP2 starting at 8 hours post release.
To further validate that nuclear localization of ndCKAP2 occurs only after com-
pletion of mitosis, HeLa cells were synchronized at the G2/M border by a thymidine-
nocodazole block. Nocodazole interferes with polymerization of microtubules; thus,
cells enter mitosis but are arrested in prometaphase. Figure 3.10a demonstrates ar-
rest by and release from thymidine-nocodazole block, as analyzed by flow cytometry
of PI-stained cells. As can be seen, cells synchronously proceed through mitosis and
enter G1 within 4 - 6 hours after release. The percentage of cells in G1, S, and
G2/M phases respectively was quantified using computational modeling and plot-
ted in Figure 3.10b. Figure 3.12 shows representative images of cells arrested by
thymidine-nocodazole block and cells 6 hours after release. As can be seen, prior to
release, most cells are rounded up and show diffuse expression of GFP-ndCKAP2
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(a) 4 - 8 hours after release from double thymidine block.
Chapter 3: Results 43
ndCKAP2DAPI
1
0
h
r
1
2
h
r
1
4
h
r
* *
*
*
* *
* *
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
(b) 10 - 14 hours after release from double thymidine block.
Figure 3.10: Synchronized HeLa cells transfected with GFP-ndCKAP2 released from
double thymidine block. As can be seen, appearance of nuclear ndCKAP2 (marked
by white stars) first occurs at 8 hours post-release from double thymidine block, and
is easily visualized.
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(b) Cell cycle analysis for synchronous
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Figure 3.11: Progression of HeLa cells through cell cycle following synchronization
through thymidine-nocodazole block. As can be seen, cells arrested at G2/M syn-
chronously proceed through mitosis and enter G1 within 4 - 6 hours.
throughout the cell; this expression does not correspond to DAPI staining of the
nucleus. After release, however, cells demonstrating nuclear GFP-ndCKAP2 are
observed. These results support the hypothesis that nuclear localization of GFP-
ndCKAP2 is not a product of onset of mitosis, but rather of completion of mitosis.
Taken as a whole, these cell cycle experiments in synchronized HeLa cell popula-
tions demonstrate that cytoplasmic ndCKAP2 translocates to the nucleus following
completion of mitosis; this translocation is unambiguous and can be used to track
mitotic cells.
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Figure 3.12: Synchronized HeLa cells transfected with GFP-ndCKAP2 before and
after release from thymidine-nocodazole block. Prior to release, most cells are arrested
at prometaphase due to the microtubule-inhibitory effects of nocodazole. At this
point (0 hr), GFP-ndCKAP2 expression is diffuse throughout the rounded cell. After
completion of mitosis, cells display nuclear GFP-ndCKAP2 (as seen at 6 hrs post-
release, marked by white stars).
3.4 ndCKAP2 demonstrates a long half-life upon
translocation to the nucleus
To demonstrate the integrative nature of GFP-ndCKAP2, the half-life of the
nuclear-localized ndCKAP2 was calculated. A schematic demonstrating the method-
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Figure 3.13: Half-life experiment cell cycle analysis. In this experiment, transfected
HeLa cells were synchronized in G1/S phase by incubation with thymidine, and then
released to proceed synchronously through exactly one cell cycle. Cells were then
incubated again with thymidine to prevent re-entry into cell cycle, allowing analysis
of cells that had proceeded through one round of mitotic division.
ology is shown in Figure 3.13a. GFP-ndCKAP2-transfected HeLa cells were synchro-
nized in G1/S by a thymidine block and released until exactly one cell cycle had been
completed. Subsequently, the cells were blocked from re-entering cell cycle by incu-
bating again with thymidine. Cells were subsequently harvested and analyzed via
immunofluorescence analysis. To verify the various cell cycle arrests, flow cytometry
was performed on PI stained cells (Figure 3.13b). These results were validated visu-
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ally as well. No nuclear-localized ndCKAP2 was seen in cells synchronized in G1/S
by the first thymidine block; however, nuclear GFP-ndCKAP2 appeared in samples
harvested 12 hours after release from thymidine block. Cells subsequently blocked by
the second incubation of thymidine demonstrated no new mitotic figures.
In the first method of determining half-life of the nuclear-localized ndCKAP2, the
fluorescence per unit area (FPUA) of nuclei of cells demonstrating nuclear-localized
ndCKAP2 was measured in cells 0 and 24 hours after initiation of the second thymi-
dine block (i.e. after completion of one synchronous round of cell cycle). >30 nuclei
were analyzed per slide, and four slides were assayed per time point. This experiment
thus allowed for a comparison of protein content (assessed by fluorescence) in the
cells. As can be seen in Figure 3.14, FPUA decreases 24 hours after completion of
synchronous cell cycle; this decrease was found to be statistically significant (p <
0.05). To calculate half-life, the following equation based on a standard model of
exponential decay was used:
FPUA(24 hrs) = FPUA(0 hrs)
(
1
2
) 24 hrs/t 1
2
where FPUA(N) represents FPUA at time N . Based on this formula and the experi-
mentally determined values, a half-life of∼75.8 hours was determined. Representative
images are seen in Figure 3.15.
One weakness of the FPUA method is that it may skew half-life in favour of high
GFP-ndCKAP2 expressors. Thus, a cell population half-life was calculated to deter-
mine the time required for 50% of cells expressing nuclear ndCKAP2 after completion
of one round of cell cycle to cease expression. The fraction of cells expressing nuclear-
localized ndCKAP2 was determined by visualizing and counting cells harvested 0
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Figure 3.14: Determination of half-life of nuclear-localized GFP-ndCKAP2 in HeLa
cells by FPUA analysis. Cells that had completed one synchronous cell cycle were
blocked from re-entering cell cycle and analyzed. Data shown is mean ± SD, with
N = 4 and > 30 nuclei counted per sample. The difference in FPUA between the 0hr
and 24 hr groups was statistically significant (p < 0.05), as determined by a one-tailed
Student’s t-test.
and 24 hours after completion of one round of cell cycle under fluorescent microscope.
>150 cells were counted per slide, and four slides were assayed per time point. As can
be seen in Figure 3.16, the proportion of cells displaying nuclear ndCKAP2 decreases
24 hours after completion of synchronous cell cycle (determined to be statistically
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Figure 3.15: Representative images of half-life analysis of nuclear ndCKAP2 in trans-
fected HeLa cells. As can be seen, FPUA decreases from 0 to 24 hours after completion
of one synchronous round of cell cycle. Nuclear ndCKAP2 is also observed 48 hours
after synchronous cell cycle, supporting the integrative nature of nuclear ndCKAP2.
significant, p < 0.05); however, this decrease is more pronounced than determined
by the FPUA method. Based on these results and using an analogous exponential
decay model similar to that used with the PFUA method, the cell population half-life
of nuclear ndCKAP2 was determined to be ∼15.84 hours. These findings suggest
that while nuclear ndCKAP2 is completely degraded in ∼65% of cells with nuclear-
localized ndCKAP2 within one cell cycle (24 hours for HeLa cells), nuclear ndCKAP2
may be visible in high expressing cells for up to several days. Imaging supports this
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Figure 3.16: Determination of cell population half-life of nuclear-localized GFP-
ndCKAP2 in HeLa cells by analysis of proportion of cells with nuclear ndCKAP2.
Cells that had completed one synchronous cell cycle were blocked from re-entering
cell cycle and analyzed. Data shown is mean ± SD, with N = 4 and > 150 cells
per sample. The difference in proportion of cells with nuclear ndCKAP2 between
the 0hr and 24 hr groups was statistically significant (p < 0.05), as determined by a
one-tailed Student’s t-test.
claim; cells displaying nuclear ndCKAP2 were observed 48 hours after completion
of synchronous cell cycle (Figure 3.15). Thus, half-life calculations demonstrate the
integrative capacity of GFP-ndCKAP2.
Chapter 4
Discussion
The aim of this investigation was to establish ndCKAP2 as a cell division probe
that could serve as a tool to assess cardiomyocyte proliferation. In particular, to meet
the challenges of assessing cardiomyocyte proliferation [14, 17, 32], it was necessary
to demonstrate that the ndCKAP2 molecular probe would be easily visualized, un-
ambiguous in identification of proliferation, and integrative in nature. To this end, an
eGFP-ndCKAP2 fusion protein was generated by subcloning into a lentiviral vector;
moreover, this vector was used to produce lentivirus carrying the molecular probe.
The expression of the probe, both by liposome-mediated transfection and viral trans-
duction, was verified in a variety of cell types, including NRCMs. The probe was
then assessed for its ability to mark mitotic events by performing cell cycle analysis
in a proliferative cell type. Finally, the half-life was calculated to demonstrate the
integrative nature of the probe.
Figures 3.6 and 3.7 shows the expression of GFP-ndCKAP2 in both immortalized
cells (HeLa, HEK293, and NIH3T3) as well as in primary cells (NRCMs and CSCs).
51
Chapter 4: Discussion 52
Examples of both cytoplasmic and nuclear figures are highlighted as well. The local-
ization of ndCKAP2 matches predictions based on prior literature [51, 52, 53]. As
can be seen in Figure 3.5, cytoplasmic ndCKAP2 shows a distinct microtubule as-
sociation, verified by staining cells with α-tubulin. Similarly, nuclear localization of
ndCKAP2 matches DAPI staining. The distinction between cytoplasmic and nuclear
ndCKAP2 is readily seen under fluorescent microscopy, thus satisfying the criteria
for the GFP-ndCKAP2 molecular probe to be easily visualized. Expression of GFP-
ndCKAP2 was successful with both transfection and transduction, satisfying the aim
to generate a fluorescent cell division probe.
Nuclear ndCKAP2 was seen in all proliferative cell types within one day of culture,
but absent in NRCMs even after one week of culture. Mammalian cardiomyocytes are
known to undergo DNA synthesis in culture [55]; indeed, staining for BrdU after one
week in culture demonstrated evidence of DNA synthesis (data not shown). Thus,
the absence of nuclear ndCKAP2 in NRCMs supports the prediction that change in
localization of ndCKAP2 is a result of mitosis and not merely DNA synthesis. To
further demonstrate that ndCKAP2 unambiguously marks mitotic events, the pres-
ence of nuclear ndCKAP2 in cells synchronously proceeding through cell cycle was
analyzed. HeLa cells transfected with GFP-ndCKAP2 were synchronized at the G1/S
border by a double thymidine block; after re-release into cell cycle, cells were serially
harvested and analyzed for localization of GFP-ndCKAP2. Figure 3.9 shows that
cells displaying nuclear ndCKAP2 are only observed after 8 hours post-release from
double thymidine block; these results correspond well to progression through cell cycle
demonstrated by both flow cytometry of PI-stained cells and PHH3 staining. More-
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over, cells with nuclear ndCKAP2 almost always appeared in pairs (as in Figure 3.10)
and closely associated; these data support the hypothesis that nuclear localization of
ndCKAP2 is a result of mitosis. In addition, thymidine-nocodazole experiments show
that localization occurs after completion of mitosis, not merely its onset. Nocodazole
arrests cells in prometaphase; however, GFP-ndCKAP2+ cells in prometaphase did
not display nuclear localization of the probe (Figure 3.12). These considerations are
particularly relevant to a probe that is proposed for use with cardiac cells. Cardiomy-
ocytes have been documented to undergo a number of abortive variants of cell cycle
[18], including DNA synthesis without division or onset of mitosis without cytokinesis
(endomitosis). GFP-ndCKAP2 unambiguously differentiates between these various
cell cycle phenomena, making it well-suited for studying proliferation in the heart.
If proliferation occurs in the heart, whether under physiological or injury condi-
tions, the rate of proliferation is likely to be very low. Thus, one of the main strengths
of GFP-ndCKAP2 as a probe for assessing cardiomyocyte proliferation is its integra-
tive nature, i.e. its ability to track mitotic events that have already happened as
opposed to merely events that are in the process of happening at time of analysis.
ndCKAP2 contains a mutation in a key region of the protein known as the KEN box,
which plays a role in binding to the anaphase-promoting complex (and promoting
breakdown of CKAP2) [52]; however, it was predicted that nuclear ndCKAP2 would
eventually be subject to breakdown pathways within the cell. Here, two methods
were utilized to determine the half-life of GFP-ndCKAP2 once translocated to the
nucleus following completion of cell division. On the basis of the events of nuclear
ndCKAP2 that “disappear” following completion of round of mitosis, the half-life
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of GFP-ndCKAP2 is approximately 16 hours (Figure 3.14). By way of comparison,
PHH3 expression begins to decline shortly after completion of anaphase. Another
recent probe used for cardiomyocyte proliferation, GFP-anillin, shows expression for
only up to 86 minutes post-mitosis [33]. However, while GFP-ndCKAP2 is broken
down in a large number of cells within completion of a second cell cycle, high expres-
sors of GFP-ndCKAP2 may continue to express nuclear ndCKAP2 for up to about 76
hours; indeed, cells displaying nuclear ndCKAP2 were seen 48 hours after thymidine
arrest following completion of one round of cell cycle. In another experiment (not
shown here), a GFP-ndCKAP2 stably-transduced HEK293 cell line was generated
via blasticidin selection. While initially all of the cells demonstrated cytoplasmic
ndCKAP2, within 2 - 3 weeks of culture cells with nuclear ndCKAP2 accumulated
and formed the majority of the line. Further analysis may be useful in understanding
the breakdown of nuclear ndCKAP2; in particular, the mechanism of breakdown of
nuclear ndCKAP2 may be of interest. It is possible that ndCKAP2 presents some
nuclear export sequence that eliminates the nuclear protein despite mutation in the
motif that mediates breakdown by ubiqutin-proteosome pathways. Future experi-
mentation may seek to uncover and manipulate such sites to improve the half-life of
nuclear ndCKAP2. Taken together, these results support the integrative nature of
ndCKAP2.
The strong expression of GFP-ndCKAP2 in NRCMs after viral transduction sug-
gests that lentivirus is a particularly suitable method for introducing the molecular
ndCKAP2 probe to cardiomyocytes for in vitro (and potentially in vivo) analysis. In
particular, lentiviral transduction of cardiomyocytes with GFP-ndCKAP2 could be
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used to assess and quantify the effects of various proposed growth factor cocktails
on cardiomyocyte proliferation in vitro. Currently, a number of studies have sug-
gested induction of cardiomyocyte cell cycle and mitosis in vitro via therapies such
as FGF1, NRG1, and periostin [38, 39, 40, 41, 42]. There is currently no standard for
determining proliferation of cardiomyocytes in these systems, and the authors alter-
natively use cell counting [40] and/or immunohistochemistry for a variety of markers
such as PHH3 or Aurora B Kinase [39, 40, 42]. Each of these methods requires com-
plex processing of the tissues. Moreover, in some experiments, the doubling time of
cardiomyocytes with treatment is as long as 4 - 5 days [41]; by way of comparison,
HeLa cells have a doubling time of 24 hours. Compared to these methods, use of GFP-
ndCKAP2 as a probe in cardiomyocytes in vitro requires little processing; cells need to
be transduced and then imaged under fluorescent microscope. The strong expression
of GFP-ndCKAP2 in NRCMs, as seen in Figure 3.7c, obviates the need for fixation
and staining as well. Thus, GFP-ndCKAP2 could prove to be a powerful standard for
ascertaining the capacity of various proposed therapeutics to induce cardiomyocyte
proliferation. Indeed, a future goal of this investigation is to test the above growth
factor therapies on NRCMs transduced with GFP-ndCKAP2. Early results failed
to replicate the claims, for example, of Engel et al. that FGF1/p38 MAPKi could
be used to stimulate cardiomyocyte proliferation (data not shown here), though the
possibility of experimental error must be ruled out before any definitive conclusions
are made about the therapeutic approach. Further work with GFP-ndCKAP2 could
be used to support the translation of proposed growth factor cocktails into clinical
trials, and may aid in the identification of new therapeutic avenues.
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Though engineered to meet the demands of cardiac systems, GFP-ndCKAP2 is not
limited in use to the study of cardiomyocyte proliferation. Figures 3.6 and 3.7 verify
the wide range of cell types with which GFP-ndCKAP2 can be used, including com-
monly used transformed cell lines such as HeLa, HEK293, and NIH3T3. Of particular
interest is that GFP-ndCKAP2 can be introduced via lentiviral transduction to stem
cells (here, human c-Kit+ cardiac stem cells) with high level of expression. Character-
izing stem cells has been a major challenge in the field of regenerative medicine and,
indeed, different stem cell lines have been shown to have greatly differing phenotype
[56]. In the cardiac stem cell field, c-Kit+ progenitors derived from different patients
have different level of expression of c-Kit as well different proliferation rates. Some
cell lines in particular proliferate at an extremely low rate. The integrative nature
of GFP-ndCKAP2 makes it an ideal probe to assess proliferation rates and doubling
time in these slowly dividing cell lines. In this sense, GFP-ndCKAP2 could be used
to characterize cell cycle behaviour for stem cell populations.
One particular weakness to the use of ndCKAP2 as a proliferation probe is that
ndCKAP2 overexpression may result in spindle defects and failure of cytokinesis [52].
Some researchers have documented the formation of monopolar mitotic spindles or
other microtubule aberrations in cells transfected with ndCKAP2, preventing pro-
gression through mitosis. Here, these results were not replicated; indeed, cell cycle
profiles of asynchronous and synchronous HeLa cells transfected with GFP-ndCKAP2
matched those of cells transfected with a GFP control (not shown here). Moreover,
in synchronous cell cycle experiments, very few cells with unusual microtubule pat-
terns were observed before or after completion of mitosis. Similarly, observations of
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the GFP-ndCKAP2 stably-transduced HEK293 cell line did not present abnormal
spindle defects similar to those reported in the literature, and GFP-ndCKAP2+ cells
continued to proliferate for several weeks. Nevertheless, the possibility that expres-
sion of ndCKAP2 may affect completion of mitosis must be considered more thor-
oughly to establish ndCKAP2 as a useful proliferation probe. One possible approach
would be to determine whether differing expression levels (as controlled by amount
of DNA/virus used to transfect/transduce cells) result in spindle defects. Careful
calibration may largely eliminate these concerns.
Thus, here a new approach to assessing cardiomyocyte proliferation has been
developed. Based on the design requirements of the cardiomyocyte system, a GFP-
ndCKAP2 molecular probe has been developed; moreover, this study establishes the
probe as being easily visualizable, unambiguous in its marking of mitotic events, and
integrative in nature. It is hoped that future applications of this molecular probe
may allow for the discovery of new insights into cardiac proliferation and renewal,
and may be used to guide the development of therapies for patients suffering from
cardiac damage and cardiomyocyte insufficiency.
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